The content on this site is intended for healthcare professionals only
Dr Karim Fizazi talks to ecancer at ESMO 2026 about long-term overall survival findings from the phase 3 PEACE-1 trial, evaluating abiraterone acetate plus prednisone in men with de novo metastatic castration-sensitive prostate cancer (mCSPC).
After a median follow-up of 7.7 years, adding abiraterone to standard of care significantly improved overall survival, reducing the risk of death by 25%. Among patients receiving androgen deprivation therapy (ADT) plus docetaxel, adding abiraterone increased median overall survival from 4.4 to 6.2 years, with 8-year survival rates rising from 27.1% to 40.3%.
Dr Fizazi explores the implications of these results for treatment intensification, including the benefits of triplet therapy across metastatic-volume subgroups.
These extended findings reinforce the importance of combining systemic treatments to improve long-term survival outcomes for patients with mCSPC.
Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer
mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity
Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer
ESMO 2025: Prostate highlights
177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC
177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity
ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC
QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC
Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer
